PDF(Pubmed)
Abstract：
Amygdalin is purported to exhibit anti-cancer properties when hydrolyzed to hydrogen cyanide (HCN). However, knowledge about amygdalin efficacy is limited. A questionnaire evaluating the efficacy, treatment, and dosing protocols, reasons for use, HCN levels, and toxicity was distributed to physicians and healers in Germany, providing amygdalin as an anti-cancer drug. Physicians (20) and healers (18) provided amygdalin over 8 (average) years to nearly 80 annually treated patients/providers. Information about amygdalin was predominantly obtained from colleagues (55%). Amygdalin was administered both intravenously (100%) and orally (32%). Intravenous application was considered to maximally delay disease progression (90%) and relieve symptoms (55%). Dosing was based on recommendations from colleagues (71%) or personal experience (47%). If limited success became apparent after an initial 3g/infusion, infusions were increased to 27g/infusion. Treatment response was primarily monitored with established (26%) and non-established tumor markers (19%). 90% did not monitor HCN levels. Negative effects were restricted to a few dizzy spells and nausea. Only 58% were willing to participate in clinical trials or contribute data for analysis (34%). Amygdalin infusions are commonly administered by healers and physicians with few side effects. The absence of standardized treatment calls for guidelines. Since intravenous application bypasses metabolization, re-evaluation of its mode of action is required.
摘要：
据称苦杏仁苷在水解为氰化氢(HCN)时表现出抗癌性质。然而,关于苦杏仁苷功效的知识是有限的。一份评估疗效的问卷，治疗,和给药方案，使用理由,HCN水平,毒性被分发给德国的医生和治疗师，提供苦杏仁苷作为抗癌药物。医师（20）和医师（18）在8（平均）年内向近80名每年接受治疗的患者/提供者提供苦杏仁苷。有关苦杏仁苷的信息主要来自同事（55％）。通过静脉内(100%)和口服(32%)施用苦杏仁苷。静脉内应用被认为最大限度地延缓疾病进展(90%)和缓解症状(55%)。给药基于同事的建议（71％）或个人经验（47％）。如果在最初的3g/输注后，有限的成功变得明显，输注增加至27g/输注。主要用已建立的(26%)和未建立的肿瘤标志物(19%)监测治疗反应。90%未监测HCN水平。负面影响仅限于一些头晕和恶心。只有58％的人愿意参加临床试验或提供分析数据（34％）。苦杏仁苷输注通常由治疗师和医生进行，副作用很少。缺乏标准化治疗需要指导。因为静脉注射会绕过代谢，需要重新评估其行动模式。
